DOE Should Probe Nonradioactive Hazards, Panel Says

WASHINGTON--The Department of Energy's troubled epidemiology program should double its research on the effects of radiation on workers and expand that research to encompass possible nonradioactive hazards, such as magnetic fields and industrial chemicals, an independent advisory panel has concluded. The DOE program is responsible for studying the health effects of radiation on humans, both by following the medical history of the survivors of the atomic bombs dropped on Japan at the end of Worl

Written byChristopher Anderson
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

WASHINGTON--The Department of Energy's troubled epidemiology program should double its research on the effects of radiation on workers and expand that research to encompass possible nonradioactive hazards, such as magnetic fields and industrial chemicals, an independent advisory panel has concluded.

The DOE program is responsible for studying the health effects of radiation on humans, both by following the medical history of the survivors of the atomic bombs dropped on Japan at the end of World War II and by comparing the radiation exposure of DOE workers with their medical records. But although the program has sponsored some research on the health effects of chemical and other nonradioactive hazards at DOE facilities, this research historically has played a relatively small part in the epidemiology program.

In an interim report submitted in late November, the panel recommended that the DOE program spend $7.5 million for research on the health effects of chemicals ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies